Form 4: ASSEMBLY BIOSCIENCES Director Susan Mahony Granted 3,500 Stock Options

ASSEMBLY BIOSCIENCES, INC. Director Susan Mahony was granted 3,500 stock options with an exercise price of $15.81, vesting by June 2026 or the 2026 annual meeting.

Summary

• Susan Mahony, a Director of ASSEMBLY BIOSCIENCES, INC. (ASMB), was granted 3,500 stock options on June 5, 2025.
• The stock options have an exercise price of $15.81 per share.
• These options will vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, assuming continuous service.
• The options have an expiration date of June 5, 2035.
• Following this transaction, Susan Mahony directly beneficially owns 3,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It is a routine compensation event, so it does not indicate significant new positive or negative developments for the company beyond standard operations.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard practice for director compensation, indicating stable corporate governance practices.

Future Outlook

The vesting schedule of the granted stock options, extending to June 2026 or the 2026 annual meeting, indicates a continued alignment of the director's incentives with the company's future performance and shareholder value creation.

Management Comments

• The grant of stock options to Director Susan Mahony is a standard component of the company's compensation structure for its non-employee directors, designed to attract and retain qualified individuals and align their interests with long-term shareholder value.

Industry Context

The grant of stock options to directors is a common compensation practice across various industries, particularly in biotechnology and growth-oriented sectors, to incentivize long-term commitment and performance. This aligns with typical industry standards for corporate governance and executive/director compensation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a widely accepted practice in the U.S. public markets, consistent with compensation structures observed in comparable biotechnology companies.
• The vesting schedule, tied to a future date or annual meeting, is also a standard mechanism to ensure continued service and alignment.
• While specific comparable companies are not mentioned in the filing, this type of equity grant is a benchmark practice for attracting and retaining board talent in the biotech sector, similar to practices at companies like Gilead Sciences or Amgen, which frequently use equity-based compensation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Susan Mahony, a director of ASSEMBLY BIOSCIENCES, INC., constitutes a related party transaction. This is a standard form of compensation for directors and is disclosed as per regulatory requirements.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align their interests with shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: While not directly impacted, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The granted stock options will vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• Following vesting, Susan Mahony will have the right to exercise these options to purchase 3,500 shares of Common Stock at the exercise price of $15.81 per share, until the expiration date of June 5, 2035.

Key Dates

Recommendation

Keywords

ASSEMBLY BIOSCIENCES, ASMB, Stock Options, Director Compensation, Equity Grant, Form 4, Insider Transaction, Susan Mahony